fenofibrate
fenofibrate is listed in the FDA National Drug Code directory with 61 NDC codes, marketed under brand names including fenofibrate, FENOFIBRATE, Fenofibrate. Available dosage forms: capsule, tablet, powder, tablet, film coated.
Drug details
- Generic Name
- fenofibrate
- Brand Names
- fenofibrate, FENOFIBRATE, Fenofibrate, Antara, Lipofen
- Application Number
- ANDA205566
- Sponsor
- Glenmark Pharmaceuticals Inc., USA
- NDC Codes
- 61
- Dosage Forms
- CAPSULE, TABLET, POWDER, TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- FENOFIBRATE
Indications and Usage
1 INDICATIONS AND USAGE Fenofibrate tablets are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7) ]. Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus [see Warnings and Precautions (5.1) and Clinical Studies (14.4) ]. Fenofibrate tablets is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL) (1). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible (1). Limitations of Use: Markedly elevated levels of serum TG (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined (1). Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized controlled trials of patients with type 2 diabetes mellitus (1).